MagForce AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
MagForce AG Announces Internal Reorganization; Appoints Co-CEO's; Reduces Headcount
MagForce Nanotechnologies AG (MagForce) announced that the Company's core functions, including clinical and business development, medical affairs plus legal & IP will be concentrated at the MagForce site in Munich where these teams are already located. Production of nanoparticles, NanoActivators, software engineering as well as the finance department will remain at the Company's registered office in Berlin. All early research activities will be reduced to a minimum and will be outsourced as deemed necessary. Moreover, the Company announced that Prof. Dr. Hoda Tawfik and Mr. Christian von Volkmann will jointly lead the Company as co-Chief Executive Officers (Co-CEO's). The headcount of MagForce will be reduced from 27 to 12.
Latest Key Developments in Biotechnology
- Avita Medical Ltd announces senior management changes
- PDL BioPharma Inc gives Q4 2013 guidance in line with analysts' estimates
- Lorus Therapeutics Inc completes $7,001,500 prospectus offering of common shares
- KaloBios Pharmaceuticals Inc announces preliminary phase 1 results in advanced hematologic malignancies with kb004, an anti-epha3 monoclonal antibody
- Share this
- Digg this